A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Latest Information Update: 17 Sep 2024
At a glance
- Drugs Niraparib (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms GALAHAD
- Sponsors Janssen Research & Development; Janssen-Cilag
- 08 Nov 2023 Status changed from active, no longer recruiting to completed.
- 01 Nov 2023 This trial has been completed in Netherland (End Date: 16 Aug 2023), according to European Clinical Trials Database record.
- 09 Oct 2023 This trial has been completed in Sweden (End Date: 16 Aug 2023), according to European Clinical Trials Database record.